Compare American Financial Group Inc (AFG) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Cytokinetics Inc — how do they compare? American Financial Group Inc trades at $144.84 (market cap $11.97B), while Cytokinetics Inc trades at $76.51 (market cap $10.63B). The key difference: American Financial Group Inc and Cytokinetics Inc are close in size by market cap, and American Financial Group Inc pays a 2.44% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AFG | CYTK | |
|---|---|---|
Market Cap | $11.97B | $10.63B |
Sector | Financials | Technology |
52-Week High | $148.71 | $87.26 |
52-Week Low | $124.18 | $34.31 |
Enterprise Value | $12.35B | $10.74B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.82, up 0.66% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 is projected at $8.2 billion with an 11.66% margin. Analysts have a consensus price target of $160.67, with 41% recommending buy.
AFG presents a positive outlook with solid earnings beats and a shareholder-friendly dividend policy, but faces risks from competitive pressures and potential market volatility. The stock's current valuation at a P/E of 12.62 offers room for growth relative to historical averages, supported by institutional interest and consistent cash flow generation.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
